Compare Bank of Montreal (BMO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs Gilead Sciences, Inc. — how do they compare? Bank of Montreal trades at $182.04 (market cap $126.83B), while Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Bank of Montreal pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| BMO | GILD | |
|---|---|---|
Market Cap | $126.83B | $168.35B |
Sector | Financials | Health |
52-Week High | $183.65 | $155.80 |
52-Week Low | $112.54 | $110.56 |
Dividend Yield | 2.69% | 2.42% |
Enterprise Value | — | $191.42B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
